
NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
pharmafile | March 4, 2020 | News story | Research and Development |Â Â Avatrombopag, NHS, NICE, UK, chronic liver diseaseÂ
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England and Wales for the treatment of thrombocytopenia in chronic liver disease patients who require surgery.
Avatrombopag has been shown to elevate platelet levels for longer periods than platelet transfusions. The recommendation provides patients with a new treatment option which can be self-administered at home, reducing the time they will need to spend in hospital.
The therapy has two list prices: for a five-day course of treatment, it costs £640 for patients with between 40,000 and 50,000 platelets per microlitre of blood, and £960 for those with less than 40,000 per microlitre.
It is estimated that around 10% of patients with chronic liver disease will need surgery in in their final two years of life.
Thrombocytopenia, or low platelet count, is the most common haematological abnormality in liver disease, which itself is on track to become the biggest cause of death in patients under the age of 65, with around 62,000 deaths a year in this age group.
Matt Fellows
Related Content

A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …

The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …

Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …






